(CercleFinance.com) – TME Pharma announces that the US FDA has granted Fast Track designation to its NOX-A12, in combination with radiotherapy and bevacizumab, for use in the treatment of aggressive brain cancer in the adult.
This designation for newly diagnosed, chemotherapy-resistant glioblastoma with measurable residual tumor post-surgery follows the FDA’s recent approval of the IND application for a phase 2 study.
The Fast Track designation aims to make new medicines deemed essential to patients more quickly available to treat serious diseases and address unmet medical needs.